Hyperlipidemia Drug Market – PCSK9 Inhibitors Drive Specialty...

added blog Wellness

2026-08-28 05:56:46 -

Hyperlipidemia Drug Market – PCSK9 Inhibitors Drive Specialty Drug Growth

PCSK9 inhibitors are becoming a major growth segment in the hyperlipidemia drug market. These injectable medicines are used in selected patients who require additional LDL-cholesterol lowering beyond what standard oral therapies can provide. While statins continue to dominate prescription volume, PCSK9 inhibitors are forecast to expand at a CAGR of 4.0% through 2035. Their growth reflects...

0 Comments 0 Shares 98 Views 0 Reviews